News | Oncology Diagnostics | March 12, 2019

Lucence Diagnostics to Develop AI Tools for Liver Cancer Treatment

Software tools would combine imaging and molecular data from liver cancer patients to help physicians make better treatment decisions

Lucence Diagnostics to Develop AI Tools for Liver Cancer Treatment

Pseudocolor accentuated CT scan image of a liver tumor. Image courtesy of Lucence Diagnostics.

March 12, 2019 — Genomic medicine company Lucence Diagnostics announced a new project to develop artificial intelligence (AI) algorithms for improving diagnosis and treatment of liver cancer. The goal is to combine the imaging and molecular data from liver cancer patients into smarter software tools that help physicians make better treatment decisions.

Lucence will be working with Olivier Gevaert, Ph.D., assistant professor of medicine (biomedical informatics) and of biomedical data science at the Stanford University School of Medicine. Having developed LiquidHallmark, which it calls the world's first liquid biopsy next-generation sequencing test that analyzes the DNA of cancer-causing mutations and viruses, Lucence will contribute its genomics expertise and proprietary sequencing technology to this project.

Liver cancer is the second leading cause of avoidable cancer deaths globally1, and hepatitis viruses contribute to the bulk of this disease. The incidence rate of liver cancer is also rising faster than any other cancer in both men and women in the United States2. The best chance of cure is surgery, and good characterization of the extent and type of the disease is critical for surgical planning. Imaging tests such as ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) play a crucial role in the visualization of liver tumors. Fusing imaging data with sequencing data that includes both cancer mutations and viral DNA will create a unique opportunity for AI-based approaches to advance liver cancer care.

This project will evaluate a dataset of more than 5,000 patients to identify image changes and patterns that are linked to diagnostic and treatment outcomes in liver cancer.

For more information: www.lucencedx.com

References

1. Knaul F.M., Arreola-Ornelas H., Rodriguez N.M., et al. Avoidable Mortality: The Core of the Global Cancer Divide. Journal of Global Oncology, Aug. 10, 2018. DOI: 10.1200/JGO.17.00190.

2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians, Jan. 8, 2019. DOI: 10.3322/caac.21551.

Related Content

CoronaCare is designed to help healthcare providers track COVID-19 (coronavirus) related symptoms of potentially infected patients. The platform enables communication with patients outside of facility walls and the ability to request the return of high-risk patients for more in-depth care. #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Coronavirus (COVID-19) | March 27, 2020
March 27, 2020 — PaxeraHealth has spent years building and be
AI vendor Infervision's InferRead CT Pneumonia software uses artificial intelligence-assisted diagnosis to improve the overall efficiency of the radiology department. It is being developed in China as a high sensitivity detection aid for novel coronavirus pneumonia (COVID-19). #COVID19 #coronavirus #SARScov2

AI vendor Infervision's InferRead CT Pneumonia software uses artificial intelligence-assisted diagnosis to improve the overall efficiency of the radiology department. It is being developed in China as a high sensitivity detection aid for novel coronavirus pneumonia (COVID-19).

Feature | Coronavirus (COVID-19) | March 27, 2020 | Jilian Liu, M.D., HIMSS Greater China
An older couple walked into the Hubei Provincial Hospital of Integrated Chinese and Western Medicine near their neigh
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Artificial Intelligence | March 24, 2020
March 24, 2020 — Qure.ai, a leading healthcare...
Instant triage capability could potentially speed up diagnosis of COVID-19 individuals and ensure resources allocated properly.
News | Artificial Intelligence | March 23, 2020
March 23, 2020 — behold.ai announced that its artificial intellige
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Representative examples of the attention heatmaps generated using Grad-CAM method for (a) COVID-19, (b) CAP, and (c) Non-Pneumonia. The heatmaps are standard Jet colormap and overlapped on the original image, the red color highlights the activation region associated with the predicted class. COVID-19 = coronavirus disease 2019, CAP = community acquired pneumonia. Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | March 20, 2020
March 20, 2020 — An arti...
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | March 19, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new